FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2761273941> ?p ?o ?g. }

• W2761273941 endingPage "206" @default.
• W2761273941 startingPage "200" @default.
• W2761273941 abstract "Abstract Aims In PEGASUS-TIMI 54, ticagrelor significantly reduced the risk of the composite of major adverse cardiovascular (CV) events by 15–16% in stable patients with a prior myocardial infarction (MI) 1–3 years earlier. We report the efficacy and safety in the subpopulation recommended for treatment in the European (EU) label, i.e. treatment with 60 mg b.i.d. initiated up to 2 years from the MI, or within 1 year after stopping previous adenosine diphosphate receptor inhibitor treatment. Methods and results Of the 21 162 patients enrolled in PEGASUS-TIMI 54, 10 779 patients were included in the primary analysis for this study, randomized to ticagrelor 60 mg (n = 5388) or matching placebo (n = 5391). The cumulative proportions of patients with events at 36 months were calculated by the Kaplan–Meier (KM) method. The composite of CV death, MI, or stroke occurred less frequently in the ticagrelor group (7.9% KM rate vs. 9.6%), hazard ratio (HR) 0.80 [95% confidence interval (CI) 0.70–0.91; P = 0.001]. Ticagrelor also reduced the risk of all-cause mortality, HR 0.80 (0.67–0.96; P = 0.018). Thrombolysis in myocardial infarction major bleeding was more frequent in the ticagrelor group 2.5% vs. 1.1%; HR 2.36 (1.65–3.39; P < 0.001). The corresponding HR for fatal or intracranial bleeding was 1.17 (0.68–2.01; P = 0.58). Conclusion In PEGASUS-TIMI 54, treatment with ticagrelor 60 mg as recommended in the EU label, was associated with a relative risk reduction of 20% in CV death, MI, or stroke. Thrombolysis in myocardial infarction major bleeding was increased, but fatal or intracranial bleeding was similar to placebo. There appears to be a favourable benefit-risk ratio for long-term ticagrelor 60 mg in this population. Clinical trial registration http://www.clinicaltrials.gov NCT01225562" @default.
• W2761273941 created "2017-10-20" @default.
• W2761273941 creator A5000771121 @default.
• W2761273941 creator A5010571732 @default.
• W2761273941 creator A5010936003 @default.
• W2761273941 creator A5015803547 @default.
• W2761273941 creator A5022267024 @default.
• W2761273941 creator A5024144703 @default.
• W2761273941 creator A5027244910 @default.
• W2761273941 creator A5030057930 @default.
• W2761273941 creator A5037745068 @default.
• W2761273941 creator A5039450208 @default.
• W2761273941 creator A5041635060 @default.
• W2761273941 creator A5043576007 @default.
• W2761273941 creator A5051592573 @default.
• W2761273941 creator A5052994249 @default.
• W2761273941 creator A5063859581 @default.
• W2761273941 creator A5064701809 @default.
• W2761273941 creator A5069534990 @default.
• W2761273941 creator A5070495078 @default.
• W2761273941 creator A5070870195 @default.
• W2761273941 creator A5088139676 @default.
• W2761273941 creator A5088708709 @default.
• W2761273941 creator A5089865834 @default.
• W2761273941 creator A5090903599 @default.
• W2761273941 date "2019-06-20" @default.
• W2761273941 modified "2023-10-14" @default.
• W2761273941 title "Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54" @default.
• W2761273941 cites W1582447064 @default.
• W2761273941 cites W1973598956 @default.
• W2761273941 cites W2002189205 @default.
• W2761273941 cites W2034514998 @default.
• W2761273941 cites W2099878930 @default.
• W2761273941 cites W2105397247 @default.
• W2761273941 cites W2125173296 @default.
• W2761273941 cites W2141358924 @default.
• W2761273941 cites W2166950143 @default.
• W2761273941 cites W2169252817 @default.
• W2761273941 cites W2749380187 @default.
• W2761273941 cites W2790804384 @default.
• W2761273941 doi "https://doi.org/10.1093/ehjcvp/pvz020" @default.
• W2761273941 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6749839" @default.
• W2761273941 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31218354" @default.
• W2761273941 hasPublicationYear "2019" @default.
• W2761273941 type Work @default.
• W2761273941 sameAs 2761273941 @default.
• W2761273941 citedByCount "23" @default.
• W2761273941 countsByYear W27612739412019 @default.
• W2761273941 countsByYear W27612739412020 @default.
• W2761273941 countsByYear W27612739412021 @default.
• W2761273941 countsByYear W27612739412022 @default.
• W2761273941 countsByYear W27612739412023 @default.
• W2761273941 crossrefType "journal-article" @default.
• W2761273941 hasAuthorship W2761273941A5000771121 @default.
• W2761273941 hasAuthorship W2761273941A5010571732 @default.
• W2761273941 hasAuthorship W2761273941A5010936003 @default.
• W2761273941 hasAuthorship W2761273941A5015803547 @default.
• W2761273941 hasAuthorship W2761273941A5022267024 @default.
• W2761273941 hasAuthorship W2761273941A5024144703 @default.
• W2761273941 hasAuthorship W2761273941A5027244910 @default.
• W2761273941 hasAuthorship W2761273941A5030057930 @default.
• W2761273941 hasAuthorship W2761273941A5037745068 @default.
• W2761273941 hasAuthorship W2761273941A5039450208 @default.
• W2761273941 hasAuthorship W2761273941A5041635060 @default.
• W2761273941 hasAuthorship W2761273941A5043576007 @default.
• W2761273941 hasAuthorship W2761273941A5051592573 @default.
• W2761273941 hasAuthorship W2761273941A5052994249 @default.
• W2761273941 hasAuthorship W2761273941A5063859581 @default.
• W2761273941 hasAuthorship W2761273941A5064701809 @default.
• W2761273941 hasAuthorship W2761273941A5069534990 @default.
• W2761273941 hasAuthorship W2761273941A5070495078 @default.
• W2761273941 hasAuthorship W2761273941A5070870195 @default.
• W2761273941 hasAuthorship W2761273941A5088139676 @default.
• W2761273941 hasAuthorship W2761273941A5088708709 @default.
• W2761273941 hasAuthorship W2761273941A5089865834 @default.
• W2761273941 hasAuthorship W2761273941A5090903599 @default.
• W2761273941 hasBestOaLocation W27612739411 @default.
• W2761273941 hasConcept C126322002 @default.
• W2761273941 hasConcept C127413603 @default.
• W2761273941 hasConcept C164705383 @default.
• W2761273941 hasConcept C207103383 @default.
• W2761273941 hasConcept C2777698277 @default.
• W2761273941 hasConcept C2777995511 @default.
• W2761273941 hasConcept C2779581417 @default.
• W2761273941 hasConcept C2780645631 @default.
• W2761273941 hasConcept C2780890252 @default.
• W2761273941 hasConcept C44249647 @default.
• W2761273941 hasConcept C500558357 @default.
• W2761273941 hasConcept C71924100 @default.
• W2761273941 hasConcept C78519656 @default.
• W2761273941 hasConceptScore W2761273941C126322002 @default.
• W2761273941 hasConceptScore W2761273941C127413603 @default.
• W2761273941 hasConceptScore W2761273941C164705383 @default.
• W2761273941 hasConceptScore W2761273941C207103383 @default.
• W2761273941 hasConceptScore W2761273941C2777698277 @default.
• W2761273941 hasConceptScore W2761273941C2777995511 @default.
• W2761273941 hasConceptScore W2761273941C2779581417 @default.
• W2761273941 hasConceptScore W2761273941C2780645631 @default.

• next